nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—UGT2B7—Epirubicin—sarcoma	0.281	0.55	CbGbCtD
Dabigatran etexilate—ABCB1—Dactinomycin—sarcoma	0.0665	0.13	CbGbCtD
Dabigatran etexilate—ABCB1—Mitoxantrone—sarcoma	0.0595	0.116	CbGbCtD
Dabigatran etexilate—ABCB1—Vincristine—sarcoma	0.0409	0.0801	CbGbCtD
Dabigatran etexilate—ABCB1—Etoposide—sarcoma	0.0375	0.0734	CbGbCtD
Dabigatran etexilate—F2—posterior vena cava—sarcoma	0.037	0.168	CbGeAlD
Dabigatran etexilate—ABCB1—Doxorubicin—sarcoma	0.0256	0.0501	CbGbCtD
Dabigatran etexilate—F2—knee—sarcoma	0.0222	0.101	CbGeAlD
Dabigatran etexilate—CES1—larynx—sarcoma	0.0128	0.0584	CbGeAlD
Dabigatran etexilate—F2—leg—sarcoma	0.0122	0.0553	CbGeAlD
Dabigatran etexilate—F2—forelimb—sarcoma	0.0121	0.0549	CbGeAlD
Dabigatran etexilate—F2—hindlimb—sarcoma	0.0109	0.0494	CbGeAlD
Dabigatran etexilate—F2—appendage—sarcoma	0.00931	0.0424	CbGeAlD
Dabigatran etexilate—UGT2B15—mammary gland—sarcoma	0.00827	0.0376	CbGeAlD
Dabigatran etexilate—F2—endothelium—sarcoma	0.00562	0.0256	CbGeAlD
Dabigatran etexilate—CES2—mammary gland—sarcoma	0.00505	0.023	CbGeAlD
Dabigatran etexilate—F2—mammary gland—sarcoma	0.00453	0.0206	CbGeAlD
Dabigatran etexilate—CES2—myometrium—sarcoma	0.00358	0.0163	CbGeAlD
Dabigatran etexilate—CES2—seminal vesicle—sarcoma	0.00324	0.0147	CbGeAlD
Dabigatran etexilate—NQO2—myometrium—sarcoma	0.0032	0.0146	CbGeAlD
Dabigatran etexilate—CES2—hematopoietic system—sarcoma	0.00308	0.014	CbGeAlD
Dabigatran etexilate—NQO2—seminal vesicle—sarcoma	0.00289	0.0132	CbGeAlD
Dabigatran etexilate—F2—hematopoietic system—sarcoma	0.00276	0.0126	CbGeAlD
Dabigatran etexilate—CES2—smooth muscle tissue—sarcoma	0.00271	0.0123	CbGeAlD
Dabigatran etexilate—CES2—skin of body—sarcoma	0.00268	0.0122	CbGeAlD
Dabigatran etexilate—F2—connective tissue—sarcoma	0.00266	0.0121	CbGeAlD
Dabigatran etexilate—UGT2B15—liver—sarcoma	0.00261	0.0119	CbGeAlD
Dabigatran etexilate—CES1—hematopoietic system—sarcoma	0.00253	0.0115	CbGeAlD
Dabigatran etexilate—CES1—connective tissue—sarcoma	0.00244	0.0111	CbGeAlD
Dabigatran etexilate—CES2—cardiac atrium—sarcoma	0.00234	0.0106	CbGeAlD
Dabigatran etexilate—CES2—uterus—sarcoma	0.00232	0.0106	CbGeAlD
Dabigatran etexilate—NQO2—cardiac atrium—sarcoma	0.00209	0.0095	CbGeAlD
Dabigatran etexilate—NQO2—uterus—sarcoma	0.00208	0.00945	CbGeAlD
Dabigatran etexilate—CES2—tendon—sarcoma	0.00204	0.00927	CbGeAlD
Dabigatran etexilate—UGT1A9—liver—sarcoma	0.00198	0.009	CbGeAlD
Dabigatran etexilate—CES2—bone marrow—sarcoma	0.00197	0.00898	CbGeAlD
Dabigatran etexilate—F2—lymphoid tissue—sarcoma	0.00194	0.00884	CbGeAlD
Dabigatran etexilate—NQO2—tendon—sarcoma	0.00182	0.00828	CbGeAlD
Dabigatran etexilate—CES1—lymphoid tissue—sarcoma	0.00178	0.00812	CbGeAlD
Dabigatran etexilate—F2—bone marrow—sarcoma	0.00177	0.00805	CbGeAlD
Dabigatran etexilate—NQO2—bone marrow—sarcoma	0.00176	0.00802	CbGeAlD
Dabigatran etexilate—CES2—testis—sarcoma	0.00169	0.00767	CbGeAlD
Dabigatran etexilate—UGT2B7—testis—sarcoma	0.00169	0.00767	CbGeAlD
Dabigatran etexilate—UGT2B7—liver—sarcoma	0.00159	0.00725	CbGeAlD
Dabigatran etexilate—CES2—liver—sarcoma	0.00159	0.00725	CbGeAlD
Dabigatran etexilate—NQO2—testis—sarcoma	0.00151	0.00686	CbGeAlD
Dabigatran etexilate—F2—liver—sarcoma	0.00143	0.00651	CbGeAlD
Dabigatran etexilate—NQO2—liver—sarcoma	0.00142	0.00648	CbGeAlD
Dabigatran etexilate—CES1—testis—sarcoma	0.00139	0.00632	CbGeAlD
Dabigatran etexilate—CES1—liver—sarcoma	0.00131	0.00597	CbGeAlD
Dabigatran etexilate—CES2—lymph node—sarcoma	0.00122	0.00556	CbGeAlD
Dabigatran etexilate—NQO2—lymph node—sarcoma	0.00109	0.00497	CbGeAlD
Dabigatran etexilate—CES1—lymph node—sarcoma	0.00101	0.00458	CbGeAlD
Dabigatran etexilate—ABCB1—myometrium—sarcoma	0.000691	0.00315	CbGeAlD
Dabigatran etexilate—ABCB1—embryo—sarcoma	0.000665	0.00303	CbGeAlD
Dabigatran etexilate—ABCB1—seminal vesicle—sarcoma	0.000625	0.00284	CbGeAlD
Dabigatran etexilate—ABCB1—hematopoietic system—sarcoma	0.000594	0.0027	CbGeAlD
Dabigatran etexilate—Angiopathy—Etoposide—sarcoma	0.000576	0.00218	CcSEcCtD
Dabigatran etexilate—Hypertension—Mitoxantrone—sarcoma	0.000574	0.00218	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Etoposide—sarcoma	0.000573	0.00217	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Etoposide—sarcoma	0.000572	0.00217	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Thiotepa—sarcoma	0.000572	0.00217	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Dactinomycin—sarcoma	0.000568	0.00215	CcSEcCtD
Dabigatran etexilate—Cardiac failure congestive—Epirubicin—sarcoma	0.000567	0.00215	CcSEcCtD
Dabigatran etexilate—Arthralgia—Mitoxantrone—sarcoma	0.000566	0.00215	CcSEcCtD
Dabigatran etexilate—Chest pain—Mitoxantrone—sarcoma	0.000566	0.00215	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Vincristine—sarcoma	0.000557	0.00211	CcSEcCtD
Dabigatran etexilate—Infection—Vincristine—sarcoma	0.000553	0.0021	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Thiotepa—sarcoma	0.000553	0.0021	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Vincristine—sarcoma	0.000546	0.00207	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Vincristine—sarcoma	0.000545	0.00207	CcSEcCtD
Dabigatran etexilate—Hepatic function abnormal—Doxorubicin—sarcoma	0.000545	0.00207	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Mitoxantrone—sarcoma	0.000542	0.00206	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Thiotepa—sarcoma	0.000542	0.00206	CcSEcCtD
Dabigatran etexilate—Fatigue—Thiotepa—sarcoma	0.000541	0.00205	CcSEcCtD
Dabigatran etexilate—Infection—Mitoxantrone—sarcoma	0.000539	0.00204	CcSEcCtD
Dabigatran etexilate—Fatigue—Dactinomycin—sarcoma	0.000537	0.00204	CcSEcCtD
Dabigatran etexilate—Constipation—Thiotepa—sarcoma	0.000537	0.00204	CcSEcCtD
Dabigatran etexilate—Back pain—Etoposide—sarcoma	0.000535	0.00203	CcSEcCtD
Dabigatran etexilate—Shock—Mitoxantrone—sarcoma	0.000534	0.00202	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Mitoxantrone—sarcoma	0.000531	0.00201	CcSEcCtD
Dabigatran etexilate—Cardiac failure—Epirubicin—sarcoma	0.000527	0.002	CcSEcCtD
Dabigatran etexilate—Skin disorder—Mitoxantrone—sarcoma	0.000527	0.002	CcSEcCtD
Dabigatran etexilate—Cardiac failure congestive—Doxorubicin—sarcoma	0.000525	0.00199	CcSEcCtD
Dabigatran etexilate—Hypotension—Vincristine—sarcoma	0.00052	0.00197	CcSEcCtD
Dabigatran etexilate—CES2—Fluoropyrimidine Activity—SMUG1—sarcoma	0.000518	0.0911	CbGpPWpGaD
Dabigatran etexilate—Osteoarthritis—Epirubicin—sarcoma	0.000514	0.00195	CcSEcCtD
Dabigatran etexilate—Pain in extremity—Epirubicin—sarcoma	0.000514	0.00195	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Epirubicin—sarcoma	0.000514	0.00195	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Thiotepa—sarcoma	0.000514	0.00195	CcSEcCtD
Dabigatran etexilate—Anaemia—Etoposide—sarcoma	0.000511	0.00194	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Dactinomycin—sarcoma	0.00051	0.00193	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Vincristine—sarcoma	0.000507	0.00192	CcSEcCtD
Dabigatran etexilate—Hypotension—Mitoxantrone—sarcoma	0.000507	0.00192	CcSEcCtD
Dabigatran etexilate—Urticaria—Thiotepa—sarcoma	0.000499	0.00189	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Thiotepa—sarcoma	0.000496	0.00188	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Mitoxantrone—sarcoma	0.000494	0.00187	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Dactinomycin—sarcoma	0.000493	0.00187	CcSEcCtD
Dabigatran etexilate—Cardiac failure—Doxorubicin—sarcoma	0.000488	0.00185	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Etoposide—sarcoma	0.000486	0.00184	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Mitoxantrone—sarcoma	0.000483	0.00183	CcSEcCtD
Dabigatran etexilate—Cough—Etoposide—sarcoma	0.000482	0.00183	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Vincristine—sarcoma	0.000481	0.00182	CcSEcCtD
Dabigatran etexilate—Fatigue—Vincristine—sarcoma	0.00048	0.00182	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Mitoxantrone—sarcoma	0.000477	0.00181	CcSEcCtD
Dabigatran etexilate—Hypertension—Etoposide—sarcoma	0.000477	0.00181	CcSEcCtD
Dabigatran etexilate—Constipation—Vincristine—sarcoma	0.000476	0.00181	CcSEcCtD
Dabigatran etexilate—Pain in extremity—Doxorubicin—sarcoma	0.000476	0.00181	CcSEcCtD
Dabigatran etexilate—Osteoarthritis—Doxorubicin—sarcoma	0.000476	0.00181	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Doxorubicin—sarcoma	0.000476	0.00181	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Epirubicin—sarcoma	0.000475	0.0018	CcSEcCtD
Dabigatran etexilate—Chest pain—Etoposide—sarcoma	0.000471	0.00178	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Epirubicin—sarcoma	0.00047	0.00178	CcSEcCtD
Dabigatran etexilate—Fatigue—Mitoxantrone—sarcoma	0.000468	0.00177	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000467	0.00177	CcSEcCtD
Dabigatran etexilate—Constipation—Mitoxantrone—sarcoma	0.000464	0.00176	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Epirubicin—sarcoma	0.000463	0.00176	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Thiotepa—sarcoma	0.000463	0.00175	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Epirubicin—sarcoma	0.00046	0.00174	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Dactinomycin—sarcoma	0.000459	0.00174	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Vincristine—sarcoma	0.000455	0.00173	CcSEcCtD
Dabigatran etexilate—Gastritis—Epirubicin—sarcoma	0.000455	0.00173	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Epirubicin—sarcoma	0.000454	0.00172	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Etoposide—sarcoma	0.000451	0.00171	CcSEcCtD
Dabigatran etexilate—Asthenia—Thiotepa—sarcoma	0.000451	0.00171	CcSEcCtD
Dabigatran etexilate—ABCB1—uterus—sarcoma	0.000448	0.00204	CbGeAlD
Dabigatran etexilate—Infection—Etoposide—sarcoma	0.000448	0.0017	CcSEcCtD
Dabigatran etexilate—Asthenia—Dactinomycin—sarcoma	0.000447	0.0017	CcSEcCtD
Dabigatran etexilate—Dysphagia—Epirubicin—sarcoma	0.000445	0.00169	CcSEcCtD
Dabigatran etexilate—Influenza—Epirubicin—sarcoma	0.000445	0.00169	CcSEcCtD
Dabigatran etexilate—Pruritus—Thiotepa—sarcoma	0.000444	0.00168	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000443	0.00168	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Etoposide—sarcoma	0.000442	0.00167	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Vincristine—sarcoma	0.00044	0.00167	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Doxorubicin—sarcoma	0.000439	0.00167	CcSEcCtD
Dabigatran etexilate—Skin disorder—Etoposide—sarcoma	0.000438	0.00166	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Doxorubicin—sarcoma	0.000435	0.00165	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Epirubicin—sarcoma	0.000433	0.00164	CcSEcCtD
Dabigatran etexilate—Urticaria—Mitoxantrone—sarcoma	0.000431	0.00163	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Thiotepa—sarcoma	0.00043	0.00163	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Mitoxantrone—sarcoma	0.000429	0.00163	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Doxorubicin—sarcoma	0.000429	0.00163	CcSEcCtD
Dabigatran etexilate—Bronchitis—Epirubicin—sarcoma	0.000428	0.00162	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Dactinomycin—sarcoma	0.000426	0.00162	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Doxorubicin—sarcoma	0.000426	0.00161	CcSEcCtD
Dabigatran etexilate—Hypotension—Etoposide—sarcoma	0.000422	0.0016	CcSEcCtD
Dabigatran etexilate—Gastritis—Doxorubicin—sarcoma	0.000421	0.0016	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Doxorubicin—sarcoma	0.00042	0.00159	CcSEcCtD
Dabigatran etexilate—ABCB1—lymphoid tissue—sarcoma	0.000418	0.0019	CbGeAlD
Dabigatran etexilate—Dizziness—Thiotepa—sarcoma	0.000415	0.00157	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Epirubicin—sarcoma	0.000413	0.00157	CcSEcCtD
Dabigatran etexilate—Influenza—Doxorubicin—sarcoma	0.000411	0.00156	CcSEcCtD
Dabigatran etexilate—Dysphagia—Doxorubicin—sarcoma	0.000411	0.00156	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Vincristine—sarcoma	0.00041	0.00156	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Etoposide—sarcoma	0.000402	0.00153	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Doxorubicin—sarcoma	0.000401	0.00152	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Mitoxantrone—sarcoma	0.0004	0.00152	CcSEcCtD
Dabigatran etexilate—Asthenia—Vincristine—sarcoma	0.0004	0.00152	CcSEcCtD
Dabigatran etexilate—Vomiting—Thiotepa—sarcoma	0.000399	0.00151	CcSEcCtD
Dabigatran etexilate—Pneumonia—Epirubicin—sarcoma	0.000399	0.00151	CcSEcCtD
Dabigatran etexilate—Infestation—Epirubicin—sarcoma	0.000396	0.0015	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Epirubicin—sarcoma	0.000396	0.0015	CcSEcCtD
Dabigatran etexilate—Vomiting—Dactinomycin—sarcoma	0.000396	0.0015	CcSEcCtD
Dabigatran etexilate—Rash—Thiotepa—sarcoma	0.000396	0.0015	CcSEcCtD
Dabigatran etexilate—Bronchitis—Doxorubicin—sarcoma	0.000396	0.0015	CcSEcCtD
Dabigatran etexilate—Dermatitis—Thiotepa—sarcoma	0.000396	0.0015	CcSEcCtD
Dabigatran etexilate—Headache—Thiotepa—sarcoma	0.000393	0.00149	CcSEcCtD
Dabigatran etexilate—Rash—Dactinomycin—sarcoma	0.000393	0.00149	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Etoposide—sarcoma	0.000389	0.00148	CcSEcCtD
Dabigatran etexilate—Asthenia—Mitoxantrone—sarcoma	0.000389	0.00148	CcSEcCtD
Dabigatran etexilate—Fatigue—Etoposide—sarcoma	0.000389	0.00147	CcSEcCtD
Dabigatran etexilate—F2—Complement and Coagulation Cascades—CR2—sarcoma	0.000387	0.0681	CbGpPWpGaD
Dabigatran etexilate—Constipation—Etoposide—sarcoma	0.000386	0.00146	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Epirubicin—sarcoma	0.000385	0.00146	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Doxorubicin—sarcoma	0.000382	0.00145	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Vincristine—sarcoma	0.000381	0.00144	CcSEcCtD
Dabigatran etexilate—ABCB1—bone marrow—sarcoma	0.000381	0.00173	CbGeAlD
Dabigatran etexilate—Haematuria—Epirubicin—sarcoma	0.000378	0.00143	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Epirubicin—sarcoma	0.000375	0.00142	CcSEcCtD
Dabigatran etexilate—Epistaxis—Epirubicin—sarcoma	0.000374	0.00142	CcSEcCtD
Dabigatran etexilate—Nausea—Thiotepa—sarcoma	0.000373	0.00141	CcSEcCtD
Dabigatran etexilate—Sinusitis—Epirubicin—sarcoma	0.000372	0.00141	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Mitoxantrone—sarcoma	0.000371	0.00141	CcSEcCtD
Dabigatran etexilate—Nausea—Dactinomycin—sarcoma	0.00037	0.0014	CcSEcCtD
Dabigatran etexilate—Pneumonia—Doxorubicin—sarcoma	0.000369	0.0014	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Etoposide—sarcoma	0.000369	0.0014	CcSEcCtD
Dabigatran etexilate—Dizziness—Vincristine—sarcoma	0.000368	0.0014	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Doxorubicin—sarcoma	0.000367	0.00139	CcSEcCtD
Dabigatran etexilate—Infestation—Doxorubicin—sarcoma	0.000367	0.00139	CcSEcCtD
Dabigatran etexilate—Urticaria—Etoposide—sarcoma	0.000358	0.00136	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Epirubicin—sarcoma	0.000358	0.00136	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Etoposide—sarcoma	0.000357	0.00135	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Doxorubicin—sarcoma	0.000357	0.00135	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Epirubicin—sarcoma	0.000356	0.00135	CcSEcCtD
Dabigatran etexilate—Vomiting—Vincristine—sarcoma	0.000354	0.00134	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Epirubicin—sarcoma	0.000351	0.00133	CcSEcCtD
Dabigatran etexilate—Rash—Vincristine—sarcoma	0.000351	0.00133	CcSEcCtD
Dabigatran etexilate—Dermatitis—Vincristine—sarcoma	0.000351	0.00133	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Epirubicin—sarcoma	0.000351	0.00133	CcSEcCtD
Dabigatran etexilate—Haematuria—Doxorubicin—sarcoma	0.00035	0.00133	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Epirubicin—sarcoma	0.00035	0.00133	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Epirubicin—sarcoma	0.000349	0.00132	CcSEcCtD
Dabigatran etexilate—Headache—Vincristine—sarcoma	0.000349	0.00132	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Doxorubicin—sarcoma	0.000347	0.00132	CcSEcCtD
Dabigatran etexilate—Epistaxis—Doxorubicin—sarcoma	0.000346	0.00131	CcSEcCtD
Dabigatran etexilate—Vomiting—Mitoxantrone—sarcoma	0.000345	0.00131	CcSEcCtD
Dabigatran etexilate—Sinusitis—Doxorubicin—sarcoma	0.000344	0.00131	CcSEcCtD
Dabigatran etexilate—Rash—Mitoxantrone—sarcoma	0.000342	0.0013	CcSEcCtD
Dabigatran etexilate—Dermatitis—Mitoxantrone—sarcoma	0.000342	0.0013	CcSEcCtD
Dabigatran etexilate—Headache—Mitoxantrone—sarcoma	0.00034	0.00129	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Etoposide—sarcoma	0.000332	0.00126	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Doxorubicin—sarcoma	0.000331	0.00126	CcSEcCtD
Dabigatran etexilate—Nausea—Vincristine—sarcoma	0.000331	0.00125	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Epirubicin—sarcoma	0.00033	0.00125	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Doxorubicin—sarcoma	0.000329	0.00125	CcSEcCtD
Dabigatran etexilate—ABCB1—testis—sarcoma	0.000325	0.00148	CbGeAlD
Dabigatran etexilate—Urinary tract disorder—Doxorubicin—sarcoma	0.000325	0.00123	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Doxorubicin—sarcoma	0.000324	0.00123	CcSEcCtD
Dabigatran etexilate—Asthenia—Etoposide—sarcoma	0.000324	0.00123	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Doxorubicin—sarcoma	0.000324	0.00123	CcSEcCtD
Dabigatran etexilate—Angiopathy—Epirubicin—sarcoma	0.000323	0.00122	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Doxorubicin—sarcoma	0.000323	0.00122	CcSEcCtD
Dabigatran etexilate—Nausea—Mitoxantrone—sarcoma	0.000322	0.00122	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Epirubicin—sarcoma	0.000321	0.00122	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Epirubicin—sarcoma	0.000321	0.00122	CcSEcCtD
Dabigatran etexilate—Pruritus—Etoposide—sarcoma	0.000319	0.00121	CcSEcCtD
Dabigatran etexilate—Malnutrition—Epirubicin—sarcoma	0.00031	0.00117	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Etoposide—sarcoma	0.000309	0.00117	CcSEcCtD
Dabigatran etexilate—ABCB1—liver—sarcoma	0.000308	0.0014	CbGeAlD
Dabigatran etexilate—Cardiac disorder—Doxorubicin—sarcoma	0.000306	0.00116	CcSEcCtD
Dabigatran etexilate—Flatulence—Epirubicin—sarcoma	0.000305	0.00116	CcSEcCtD
Dabigatran etexilate—CES1—Fluoropyrimidine Activity—SMUG1—sarcoma	0.000305	0.0537	CbGpPWpGaD
Dabigatran etexilate—Back pain—Epirubicin—sarcoma	0.0003	0.00114	CcSEcCtD
Dabigatran etexilate—Angiopathy—Doxorubicin—sarcoma	0.000299	0.00113	CcSEcCtD
Dabigatran etexilate—Dizziness—Etoposide—sarcoma	0.000298	0.00113	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Doxorubicin—sarcoma	0.000297	0.00113	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Doxorubicin—sarcoma	0.000297	0.00113	CcSEcCtD
Dabigatran etexilate—Vomiting—Etoposide—sarcoma	0.000287	0.00109	CcSEcCtD
Dabigatran etexilate—Malnutrition—Doxorubicin—sarcoma	0.000287	0.00109	CcSEcCtD
Dabigatran etexilate—Anaemia—Epirubicin—sarcoma	0.000286	0.00109	CcSEcCtD
Dabigatran etexilate—Rash—Etoposide—sarcoma	0.000284	0.00108	CcSEcCtD
Dabigatran etexilate—Dermatitis—Etoposide—sarcoma	0.000284	0.00108	CcSEcCtD
Dabigatran etexilate—Headache—Etoposide—sarcoma	0.000283	0.00107	CcSEcCtD
Dabigatran etexilate—Flatulence—Doxorubicin—sarcoma	0.000282	0.00107	CcSEcCtD
Dabigatran etexilate—Syncope—Epirubicin—sarcoma	0.000278	0.00105	CcSEcCtD
Dabigatran etexilate—Back pain—Doxorubicin—sarcoma	0.000277	0.00105	CcSEcCtD
Dabigatran etexilate—Palpitations—Epirubicin—sarcoma	0.000274	0.00104	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Epirubicin—sarcoma	0.000272	0.00103	CcSEcCtD
Dabigatran etexilate—Cough—Epirubicin—sarcoma	0.00027	0.00103	CcSEcCtD
Dabigatran etexilate—Nausea—Etoposide—sarcoma	0.000268	0.00102	CcSEcCtD
Dabigatran etexilate—Hypertension—Epirubicin—sarcoma	0.000267	0.00101	CcSEcCtD
Dabigatran etexilate—Anaemia—Doxorubicin—sarcoma	0.000265	0.001	CcSEcCtD
Dabigatran etexilate—Chest pain—Epirubicin—sarcoma	0.000264	0.001	CcSEcCtD
Dabigatran etexilate—Arthralgia—Epirubicin—sarcoma	0.000264	0.001	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000262	0.000993	CcSEcCtD
Dabigatran etexilate—Syncope—Doxorubicin—sarcoma	0.000257	0.000975	CcSEcCtD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—TEK—sarcoma	0.000254	0.0447	CbGpPWpGaD
Dabigatran etexilate—Palpitations—Doxorubicin—sarcoma	0.000253	0.000961	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Epirubicin—sarcoma	0.000253	0.000959	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Doxorubicin—sarcoma	0.000252	0.000955	CcSEcCtD
Dabigatran etexilate—Infection—Epirubicin—sarcoma	0.000251	0.000953	CcSEcCtD
Dabigatran etexilate—Cough—Doxorubicin—sarcoma	0.00025	0.000949	CcSEcCtD
Dabigatran etexilate—Shock—Epirubicin—sarcoma	0.000249	0.000943	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Epirubicin—sarcoma	0.000248	0.00094	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Epirubicin—sarcoma	0.000248	0.000939	CcSEcCtD
Dabigatran etexilate—Hypertension—Doxorubicin—sarcoma	0.000247	0.000939	CcSEcCtD
Dabigatran etexilate—Skin disorder—Epirubicin—sarcoma	0.000246	0.000931	CcSEcCtD
Dabigatran etexilate—Arthralgia—Doxorubicin—sarcoma	0.000244	0.000926	CcSEcCtD
Dabigatran etexilate—Chest pain—Doxorubicin—sarcoma	0.000244	0.000926	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000242	0.000919	CcSEcCtD
Dabigatran etexilate—Hypotension—Epirubicin—sarcoma	0.000236	0.000896	CcSEcCtD
Dabigatran etexilate—ABCB1—lymph node—sarcoma	0.000236	0.00107	CbGeAlD
Dabigatran etexilate—Anaphylactic shock—Doxorubicin—sarcoma	0.000234	0.000887	CcSEcCtD
Dabigatran etexilate—Infection—Doxorubicin—sarcoma	0.000232	0.000881	CcSEcCtD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—ANGPT2—sarcoma	0.000232	0.0409	CbGpPWpGaD
Dabigatran etexilate—Musculoskeletal discomfort—Epirubicin—sarcoma	0.00023	0.000874	CcSEcCtD
Dabigatran etexilate—Shock—Doxorubicin—sarcoma	0.00023	0.000873	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Doxorubicin—sarcoma	0.000229	0.00087	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Doxorubicin—sarcoma	0.000229	0.000869	CcSEcCtD
Dabigatran etexilate—Skin disorder—Doxorubicin—sarcoma	0.000227	0.000862	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Epirubicin—sarcoma	0.000225	0.000855	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Epirubicin—sarcoma	0.000223	0.000844	CcSEcCtD
Dabigatran etexilate—Hypotension—Doxorubicin—sarcoma	0.000219	0.000829	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Epirubicin—sarcoma	0.000218	0.000828	CcSEcCtD
Dabigatran etexilate—Fatigue—Epirubicin—sarcoma	0.000218	0.000827	CcSEcCtD
Dabigatran etexilate—Constipation—Epirubicin—sarcoma	0.000216	0.00082	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Doxorubicin—sarcoma	0.000213	0.000808	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Doxorubicin—sarcoma	0.000209	0.000791	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Epirubicin—sarcoma	0.000207	0.000784	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Doxorubicin—sarcoma	0.000206	0.000781	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000202	0.000766	CcSEcCtD
Dabigatran etexilate—Fatigue—Doxorubicin—sarcoma	0.000202	0.000765	CcSEcCtD
Dabigatran etexilate—F2—Syndecan-4-mediated signaling events—CXCR4—sarcoma	0.000201	0.0354	CbGpPWpGaD
Dabigatran etexilate—Urticaria—Epirubicin—sarcoma	0.000201	0.000762	CcSEcCtD
Dabigatran etexilate—Constipation—Doxorubicin—sarcoma	0.0002	0.000759	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Epirubicin—sarcoma	0.0002	0.000758	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Doxorubicin—sarcoma	0.000191	0.000725	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Epirubicin—sarcoma	0.000186	0.000706	CcSEcCtD
Dabigatran etexilate—Urticaria—Doxorubicin—sarcoma	0.000186	0.000705	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Doxorubicin—sarcoma	0.000185	0.000701	CcSEcCtD
Dabigatran etexilate—Asthenia—Epirubicin—sarcoma	0.000181	0.000688	CcSEcCtD
Dabigatran etexilate—Pruritus—Epirubicin—sarcoma	0.000179	0.000678	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Epirubicin—sarcoma	0.000173	0.000656	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Doxorubicin—sarcoma	0.000172	0.000654	CcSEcCtD
Dabigatran etexilate—F2—Vitamin B12 Metabolism—HBA1—sarcoma	0.000169	0.0297	CbGpPWpGaD
Dabigatran etexilate—Asthenia—Doxorubicin—sarcoma	0.000168	0.000637	CcSEcCtD
Dabigatran etexilate—Dizziness—Epirubicin—sarcoma	0.000167	0.000634	CcSEcCtD
Dabigatran etexilate—Pruritus—Doxorubicin—sarcoma	0.000166	0.000628	CcSEcCtD
Dabigatran etexilate—Vomiting—Epirubicin—sarcoma	0.000161	0.00061	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Doxorubicin—sarcoma	0.00016	0.000607	CcSEcCtD
Dabigatran etexilate—Rash—Epirubicin—sarcoma	0.000159	0.000605	CcSEcCtD
Dabigatran etexilate—Dermatitis—Epirubicin—sarcoma	0.000159	0.000604	CcSEcCtD
Dabigatran etexilate—Headache—Epirubicin—sarcoma	0.000158	0.000601	CcSEcCtD
Dabigatran etexilate—Dizziness—Doxorubicin—sarcoma	0.000155	0.000587	CcSEcCtD
Dabigatran etexilate—Nausea—Epirubicin—sarcoma	0.00015	0.00057	CcSEcCtD
Dabigatran etexilate—Vomiting—Doxorubicin—sarcoma	0.000149	0.000564	CcSEcCtD
Dabigatran etexilate—Rash—Doxorubicin—sarcoma	0.000148	0.000559	CcSEcCtD
Dabigatran etexilate—Dermatitis—Doxorubicin—sarcoma	0.000147	0.000559	CcSEcCtD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—TEK—sarcoma	0.000147	0.0259	CbGpPWpGaD
Dabigatran etexilate—Headache—Doxorubicin—sarcoma	0.000147	0.000556	CcSEcCtD
Dabigatran etexilate—F2—Regulation of IGF Activity by IGFBP—MMP2—sarcoma	0.00014	0.0247	CbGpPWpGaD
Dabigatran etexilate—Nausea—Doxorubicin—sarcoma	0.000139	0.000527	CcSEcCtD
Dabigatran etexilate—CES2—Fluoropyrimidine Activity—TP53—sarcoma	0.000137	0.0242	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—HBA1—sarcoma	0.000137	0.0242	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—ANGPT2—sarcoma	0.000135	0.0237	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	0.000113	0.0198	CbGpPWpGaD
Dabigatran etexilate—F2—Selenium Micronutrient Network—HBA1—sarcoma	0.000109	0.0192	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—EZR—sarcoma	0.000106	0.0187	CbGpPWpGaD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—FOXO1—sarcoma	0.000104	0.0183	CbGpPWpGaD
Dabigatran etexilate—CES2—E2F transcription factor network—MYC—sarcoma	8.87e-05	0.0156	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—PLCG1—sarcoma	8.48e-05	0.0149	CbGpPWpGaD
Dabigatran etexilate—F2—FOXA2 and FOXA3 transcription factor networks—CREB1—sarcoma	8.35e-05	0.0147	CbGpPWpGaD
Dabigatran etexilate—CES1—Fluoropyrimidine Activity—TP53—sarcoma	8.1e-05	0.0143	CbGpPWpGaD
Dabigatran etexilate—F2—Angiopoietin receptor Tie2-mediated signaling—MMP2—sarcoma	7.02e-05	0.0123	CbGpPWpGaD
Dabigatran etexilate—F2—Thrombin signalling through proteinase activated receptors (PARs)—SRC—sarcoma	6.95e-05	0.0122	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—PPAR Alpha Pathway—CCND1—sarcoma	6.95e-05	0.0122	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet Aggregation (Plug Formation)—SRC—sarcoma	6.19e-05	0.0109	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—VEGFC—sarcoma	5.68e-05	0.00999	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—PPAR Alpha Pathway—MYC—sarcoma	5.57e-05	0.0098	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—NPM1—sarcoma	5.55e-05	0.00976	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—sarcoma	5.27e-05	0.00926	CbGpPWpGaD
Dabigatran etexilate—CES1—E2F transcription factor network—MYC—sarcoma	5.23e-05	0.0092	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Constitutive Androstane Receptor Pathway—FOXO1—sarcoma	5.16e-05	0.00908	CbGpPWpGaD
Dabigatran etexilate—F2—Peptide ligand-binding receptors—CXCR4—sarcoma	4.84e-05	0.00851	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL2—sarcoma	4.52e-05	0.00794	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—IL2—sarcoma	4.46e-05	0.00785	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—JUN—sarcoma	4.39e-05	0.00773	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—PDGFRB—sarcoma	4.33e-05	0.00762	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—PDGFRA—sarcoma	4.26e-05	0.0075	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TEK—sarcoma	3.99e-05	0.00701	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—SRC—sarcoma	3.94e-05	0.00693	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—CXCR4—sarcoma	3.92e-05	0.00689	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRB—sarcoma	3.67e-05	0.00645	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—ANGPT2—sarcoma	3.65e-05	0.00642	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—sarcoma	3.61e-05	0.00635	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—sarcoma	3.45e-05	0.00607	CbGpPWpGaD
Dabigatran etexilate—F2—Class A/1 (Rhodopsin-like receptors)—CXCR4—sarcoma	3.24e-05	0.00571	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—VEGFC—sarcoma	2.93e-05	0.00515	CbGpPWpGaD
Dabigatran etexilate—F2—Folate Metabolism—TP53—sarcoma	2.87e-05	0.00504	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—SRC—sarcoma	2.82e-05	0.00495	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—sarcoma	2.8e-05	0.00492	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—NRAS—sarcoma	2.71e-05	0.00477	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR ligand binding—CXCR4—sarcoma	2.47e-05	0.00435	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—PDGFRA—sarcoma	2.46e-05	0.00433	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—CREB1—sarcoma	2.35e-05	0.00413	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—KRAS—sarcoma	2.33e-05	0.0041	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PLCG1—sarcoma	2.3e-05	0.00405	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—sarcoma	2.29e-05	0.00403	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—ENO2—sarcoma	2.25e-05	0.00396	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—HBA1—sarcoma	2.24e-05	0.00393	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—CREB1—sarcoma	2.1e-05	0.00369	CbGpPWpGaD
Dabigatran etexilate—F2—Cell surface interactions at the vascular wall—HRAS—sarcoma	1.98e-05	0.00349	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—NRAS—sarcoma	1.95e-05	0.00344	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PLCG1—sarcoma	1.91e-05	0.00336	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—EGFR—sarcoma	1.78e-05	0.00313	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—IL2—sarcoma	1.7e-05	0.00299	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—KRAS—sarcoma	1.68e-05	0.00296	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—sarcoma	1.54e-05	0.00271	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—JUN—sarcoma	1.51e-05	0.00266	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—SRC—sarcoma	1.48e-05	0.00261	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—sarcoma	1.46e-05	0.00256	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—VEGFA—sarcoma	1.44e-05	0.00254	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CXCR4—sarcoma	1.4e-05	0.00246	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—IL2—sarcoma	1.34e-05	0.00236	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—sarcoma	1.33e-05	0.00233	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—VEGFA—sarcoma	1.32e-05	0.00232	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CXCR4—sarcoma	1.27e-05	0.00223	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—sarcoma	1.25e-05	0.00221	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—sarcoma	1.22e-05	0.00214	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TLE1—sarcoma	1.18e-05	0.00207	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—VEGFA—sarcoma	1.14e-05	0.00201	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—sarcoma	1.07e-05	0.00187	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ENO2—sarcoma	1.02e-05	0.0018	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—HBA1—sarcoma	1.02e-05	0.00179	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—VEGFC—sarcoma	9.92e-06	0.00175	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CREB1—sarcoma	8.97e-06	0.00158	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—IL2—sarcoma	8.75e-06	0.00154	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PLCG1—sarcoma	8.7e-06	0.00153	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—MMP2—sarcoma	8.67e-06	0.00152	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ENO2—sarcoma	8.33e-06	0.00146	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—HBA1—sarcoma	8.28e-06	0.00146	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FLT1—sarcoma	7.93e-06	0.0014	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PLCG1—sarcoma	7.8e-06	0.00137	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—SRC—sarcoma	7.63e-06	0.00134	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CXCR4—sarcoma	7.49e-06	0.00132	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—VEGFA—sarcoma	7.44e-06	0.00131	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—sarcoma	7.42e-06	0.00131	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ATF1—sarcoma	7.41e-06	0.0013	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—NRAS—sarcoma	7.34e-06	0.00129	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PLCG1—sarcoma	7.07e-06	0.00124	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CREB1—sarcoma	6.79e-06	0.00119	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—CTNNB1—sarcoma	6.64e-06	0.00117	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—sarcoma	6.46e-06	0.00114	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—sarcoma	6.45e-06	0.00113	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—sarcoma	6.4e-06	0.00113	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—KRAS—sarcoma	6.32e-06	0.00111	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IGF1R—sarcoma	5.81e-06	0.00102	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—sarcoma	5.79e-06	0.00102	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—sarcoma	5.64e-06	0.000991	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TP53—sarcoma	5.62e-06	0.000988	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FOXO1—sarcoma	5.53e-06	0.000973	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—IL2—sarcoma	5.53e-06	0.000973	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PDGFRB—sarcoma	5.52e-06	0.000971	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PDGFRA—sarcoma	5.44e-06	0.000956	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—HRAS—sarcoma	5.37e-06	0.000945	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—sarcoma	5.19e-06	0.000912	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—sarcoma	5.07e-06	0.000892	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL2—sarcoma	5.02e-06	0.000883	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—sarcoma	4.79e-06	0.000843	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KDR—sarcoma	4.58e-06	0.000805	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—sarcoma	4.26e-06	0.000749	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KIT—sarcoma	4.22e-06	0.000741	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—NRAS—sarcoma	4.22e-06	0.000741	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CREB1—sarcoma	4.01e-06	0.000706	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—EGFR—sarcoma	3.84e-06	0.000676	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ENO2—sarcoma	3.82e-06	0.000672	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—HBA1—sarcoma	3.8e-06	0.000668	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—KRAS—sarcoma	3.63e-06	0.000638	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MDM2—sarcoma	3.32e-06	0.000584	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PLCG1—sarcoma	3.24e-06	0.00057	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—HRAS—sarcoma	3.08e-06	0.000542	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL2—sarcoma	2.97e-06	0.000522	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCND1—sarcoma	2.89e-06	0.000509	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—JUN—sarcoma	2.89e-06	0.000508	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CTNNB1—sarcoma	2.86e-06	0.000504	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SRC—sarcoma	2.59e-06	0.000455	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—VEGFA—sarcoma	2.52e-06	0.000443	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NRAS—sarcoma	2.49e-06	0.000438	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MYC—sarcoma	2.32e-06	0.000408	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EGFR—sarcoma	2.27e-06	0.000399	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KRAS—sarcoma	2.14e-06	0.000377	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TP53—sarcoma	1.9e-06	0.000335	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HRAS—sarcoma	1.82e-06	0.00032	CbGpPWpGaD
